Post-marketing surveys

Clinical trial is the major tool to prove your innovation but post-marketing surveys (PMS) allow, under real-life conditions, to improve the knowledge on clinical and/or safety data, to establish risk management plan, and to support a long-term marketing development of your product.

PMS deal with marketed products that are prescribed in the usual manner and used in accordance with the approved label. There are no protocol-specific interventions/procedures. Therapeutic strategy, as well as decisions of management and follow-up, is strictly under the physician’s responsibility as per usual practice, and prescription is clearly separated from the decision to include the patient in the study. Moreover, epidemiological methods are used for statistical data analysis.

Which type of PMS for your study?

The study design is to be deeply discussed with our methodologists as the whole success of your project depends on it.

Here are the different types of PMS that can be proposed to you.

  • Cohort studies and registries are an irreplaceable way to document real-life performance and safety of a drug.
  • Case-control and other retrospective studies may be a great help in investigating rare adverse events.
  • Cross-sectional surveys may be used to precise the epidemiology of a condition, for instance to identify the target population of a drug.
  • Phone surveys and polls.
  • Medico-economic evaluations.
  • Post authorization safety studies (PASS): investigate the frequency of already known adverse events and possible rare adverse events not yet identified.

Our Services for your PMS:

As for clinical trials, each PMS is handled by a dedicated project manager who can rely on an international operational team composed of operation assistants and epidemiological research associates (ERAs) who are able to travel all over Europe for the needs of your study.

Please feel free to contact us for further information and a personalised advice.

Let clinical evidence
support innovation

Follow us: LinkedIn Twitter rss

Applications

Sample size / continuous outcome Sample size / binary outcome Sample size / time-to-event outcome

News

Morning Read: Non-profit designing free Wi-Fi architecture for hospitals >> Read

Managing retinal vein occlusion >> Read

Let Me Die on the Prairie by Frances Jane Crosby Van Alstyne >> Read

Publication: Volume 16, number 4 (Stevenson). Study found that no conclusive results can be provided on the cost-effectiveness of four non-invasive tests for liver fibrosis [the Enhanced Liver Fibrosis Test, FibroTest and FibroMAX and transient elastography (FibroScan)] in patients suspected of having alcohol-related liver disease. >> Read

Top headlines from HIMSS2012 (Tuesday edition) >> Read

Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis >> Read

Publication: Volume 16, number 3 (Hockenhull). Report finds that whilst some interventions targeted at mental health populations to reduce violence are well supported by the evidence a scattergun approach in the research literature provides little firm evidence for the majority of interventions. Evidence shows small-to-moderate effects for cognitive behavioural therapy for psychological interventions, and larger effects for atypical antipsychotic drugs. >> Read

How the NHS measures up to other health systems >> Read

Publication: Volume 16, number 5 (Ara). Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. >> Read

Peter John Fenton >> Read

Publication: Volume 16, number 6 (Reeves). The verteporfin photodynamic therapy cohort study found that treatment and follow-up were much less frequent in routine clinical practice than in research trials and the cost-effectiveness was similar to the highest previous estimate. >> Read

Frederick Valentine Flynn >> Read